Patents Assigned to Novartis AG
  • Patent number: 10292783
    Abstract: An ophthalmic illumination system includes a light source generating a source light beam and a beam splitter splitting the source light beam into first and second light beams. A first attenuator is located in a path of the first light beam and a second attenuator is located in the path of the second light beam, the first and second attenuators operable to change the intensities of the first and second light beams, respectively. A first optical fiber port is configured for connection to a first optical fiber for delivering the first light beam to a patient's eye and a second optical fiber port is configured for connection to a second optical fiber for delivering the second light beam to the patient's eye. A control unit is communicatively coupled to the first and second attenuators and is operable to adjust the attenuators to control the intensities of the light beams delivered to the patient's eye.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: May 21, 2019
    Assignee: Novartis AG
    Inventors: Gerald D. Bacher, Steven T. Charles, Eyad Ammari, Paul Hallen, Michael Papac, Ronald T. Smith
  • Patent number: 10294010
    Abstract: The invention relates to a dispensing device for metering and dispensing a predetermined number of multiparticulates from a container. The dispensing device comprises a chamber which includes an inlet through which multiparticulates can enter the chamber and an overflow through which multiparticulates can leave the chamber. There is also an outlet through which multiparticulates can be dispensed from the chamber. The chamber comprises a metering surface which includes at least one retaining portion. The, or each, of the retaining portions is configured to be able to releasably retain a single multiparticulate.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: May 21, 2019
    Assignee: Novartis AG
    Inventors: Sabine Desset-Brethes, Regis Frelon, Stefan Hirsch, Hans Jensen, Esben Johansen, Peter Mathiasen, Jan Olesen
  • Patent number: 10294934
    Abstract: Devices, systems, and methods including a lubricating solution bath for a pump integrated into an ophthalmic surgical hand piece are provided. In some embodiments, an ophthalmic pump system includes a housing defining a cavity. The system includes a rotating element positioned within the cavity of the housing. The system includes a flexible tubular structure positioned within the housing adjacent to the rotating element such that rotation of the rotation element urges a fluid through the flexible tubular structure. The system includes a lubricating solution positioned within the cavity around the rotating element and at least a portion of the flexible tubular structure.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: May 21, 2019
    Assignee: Novartis AG
    Inventors: John Morgan Bourne, Glenn Robert Sussman
  • Patent number: 10285583
    Abstract: A scanning optical probe and method includes a cannula, optical fiber, lens, and an actuating mechanism for tilting the optical fiber back and forth within the cannula. An actuator in the probe handle is coupled to various flexing and guide components extending through the cannula and towards the distal end of the scanning optical probe. Reciprocating motion from the actuator is transmitted to the components thereby causing the optical fiber at the distal end of the scanning optical probe to aim across target surfaces. The light emitted from the optical fiber is processed to generate a scan of the target area.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventors: Kambiz Parto, Edouard G. Schmidtlin, Barry L. Wheatley
  • Patent number: 10285588
    Abstract: An indirect contact lens is mechanically coupled to a surgical microscope during ophthalmic surgery, such as vitreoretinal surgery. The indirect contact lens rests on a cornea of an eye of a patient during the surgery but is supported by a surgical microscope attachment having multiple degrees of freedom to accommodate small movements of the eye while remaining aligned to an optical axis of the surgical microscope.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventors: Ron Smith, Tammo Heeren, Steve Charles
  • Patent number: 10286069
    Abstract: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventors: Joan Mannick, David Glass, Leon Murphy
  • Patent number: 10285806
    Abstract: A multifocal ophthalmic lens includes an ophthalmic lens and a diffractive element. The ophthalmic lens has a base curvature corresponding to a base power. The diffractive element produces constructive interference in at least four consecutive diffractive orders corresponding a range of vision between near and distance vision. The constructive interference produces a near focus, a distance focus corresponding to the base power of the ophthalmic lens, and an intermediate focus between the near focus and the distance focus.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventors: Myoung-Taek Choi, Xin Hong, Yueai Liu
  • Patent number: 10287354
    Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 14, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
  • Patent number: 10287370
    Abstract: The invention is related to a class of hydrophilic polymers each comprising one sole thiol-containing terminal group. The hydrophilic polymers are highly reactive towards azetidinium groups of an azetidinium-containing polymer upon heating and can find particular use in for producing water-soluble highly-branched hydrophilic polymeric material useful for producing water gradient contact lenses.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventors: Frank Chang, Troy Vernon Holland, Thomas M. Moy
  • Patent number: 10287324
    Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 14, 2019
    Assignee: NOVARTIS AG
    Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
  • Patent number: 10287266
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Jorge Garcia Fortanet, Andriana Jouk, Rajesh Karki, Matthew J. LaMarche, Gang Liu, Mark G. Palermo, Lawrence Blas Perez, Patrick James Sarver, Michael David Shultz, Martin Sendzik, Bakary-Barry Toure, Bing Yu
  • Patent number: 10285802
    Abstract: Described herein is an extension device to extend ocular tissue within an irideocorneal angle of an eye of a patient, comprising a flexible body and a plurality of tensioning features disposed on the body. The body is sized and configured to be disposed within the irideocorneal angle. The body has a curved longitudinal axis, a channel extending from a first end to a second end, an inner convex side, and an outer concave side. The body is flexible between a first flexed condition and a second unflexed condition. The body has a first radius of curvature in the first flexed condition and a second radius of curvature in the unflexed condition. Each tensioning feature is shaped and sized to grasp the ocular tissue within the irideocorneal angle.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventor: Andrew David Johnson
  • Patent number: 10285584
    Abstract: En face or 3D volumetric OCT imaging during ophthalmic surgery may be performed with an OCT scanning controller that interfaces to an OCT scanner used with a surgical microscope. The OCT scanner may generate en face images before and after surgical operations, such as retinal membrane peeling, are performed. Using digital subtraction on the en face images, an overlay image indicative of the changes from the surgical operations to the eye may be generated and overlaid onto an optical image displayed to a user of the surgical microscope.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventors: Steven T. Charles, Lingfeng Yu, Hugang Ren
  • Publication number: 20190135913
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: September 13, 2018
    Publication date: May 9, 2019
    Applicant: NOVARTIS AG
    Inventors: Joy GHOSH, Mark Anthony RUTZ, Kathrin Ulrike TISSOT-DAGUETTE, Igor SPLAWSKI, Michael ROGUSKA
  • Patent number: 10278811
    Abstract: A multifocal ophthalmic lens includes an ophthalmic lens and a diffractive element. The ophthalmic lens has a base curvature corresponding to a base power. The diffractive element produces constructive interference in at least four consecutive diffractive orders corresponding a range of vision between near and distance vision. The constructive interference produces a near focus, a distance focus corresponding to the base power of the ophthalmic lens, and an intermediate focus between the near focus and the distance focus. A diffraction efficiency of at least one of the diffractive orders is suppressed to less than ten percent.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: May 7, 2019
    Assignee: Novartis AG
    Inventors: Myoung-Taek Choi, Xin Hong, Yueai Liu
  • Patent number: 10280139
    Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: May 7, 2019
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Patent number: 10278785
    Abstract: A process of making a diverging-light fiber optics illumination delivery system includes providing a micro-post comprising a glass-ceramic light-scattering element that includes at least one of a ceramic, a glass ceramic, an immiscible glass, a porous glass, opal glass, amorphous glass, an aerated glass, and a nanostructured glass; and fusion-splicing the glass-ceramic micro-post to the optical fiber by pulling an arc between electrodes across a gap formed by the optical fiber and the glass-ceramic micro-post; maintaining the arc for a time sufficiently long to make facing surfaces of the optical fiber and the micro-post one of malleable and molten; and pushing and thereby fusing together the facing surfaces of the optical fiber and the micro-post. Some embodiments can include fusing the glass-ceramic micro-post to the optical fiber by applying a laser beam to heat up at least one of the facing surfaces of the optical fiber and the glass-ceramic micro-post.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: May 7, 2019
    Assignee: Novartis AG
    Inventors: Alireza Mirsepassi, Ronald T. Smith, Michael J. Papac, Chenguang Diao
  • Patent number: 10278861
    Abstract: A phacoemulsification system that includes a hand-graspable body and a phacoemulsification needle extending from a distal portion of the body is disclosed herein. The phacoemulsification system may also include an impeller pump carried by the hand-graspable body and configured to convey an aspiration fluid from a surgical site. The impeller pump may include an aspiration motor and a flexible impeller coupled to and rotatably driven by the aspiration motor. The flexible impeller may be arranged to aspirate fluid and emulsified lens tissue from the surgical site.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: May 7, 2019
    Assignee: Novartis AG
    Inventor: John Morgan Bourne
  • Patent number: 10278969
    Abstract: The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: May 7, 2019
    Assignee: Novartis AG
    Inventor: Suzie Ribeiro
  • Publication number: 20190127112
    Abstract: In a reclosable folding box (41, 42, 43) having a safety and tamper-evident closure (84), the side wall surfaces (2 to 6, 64, 65) of which are formed by a one-piece blank (1, 1a, 1b) and glued together in such a way that the folding box (41, 42, 43) cannot be opened without destroying a glued joint and/or at least one disconnectable tear line area (16, 17, 16a, 16b, 17a, 17b), a solution for a reclosable medical packaging having a safety and tamper-evident closure is to be created, which provides an improved graspability and visual recognizability of a pull tab forming at least the substantial part of the safety and tamper-evident closure.
    Type: Application
    Filed: April 6, 2017
    Publication date: May 2, 2019
    Applicant: Novartis AG
    Inventor: Ian Andrew GRAY